<DOC>
	<DOCNO>NCT03056573</DOCNO>
	<brief_summary>Expand indication Portico TF Delivery System obtain approval Alternative Access Delivery System</brief_summary>
	<brief_title>Assessment St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access</brief_title>
	<detailed_description>Expand indication Portico TF Delivery System obtain approval Alternative Access Delivery System place Portico transcatheter aortic valve alternative access site , specifically subclavian/axillary transaortic ( TAo ) subject symptomatic severe native aortic stenosis consider high surgical risk</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject provide write informed consent prior uploading CT scan core lab . 2 . Subject 65 year age old time index procedure , and/or comorbidities , opinion Principal Investigator Subject Selection Committee , preclude surgical valve replacement . 3 . Subject 's aortic annulus diameter meet range indicated Instructions Use measure multislice CT conduct within 180 day prior index procedure . 4 . Subject senile degenerative aortic stenosis see echocardiography within 90 day index procedure measure : mean gradient &gt; 40 mmHg jet velocity great 4.0 m/s Doppler Velocity Index &lt; 0.25 , initial aortic valve area ( AVA ) ≤ 1.0 cm2 ( indexed EOA ≤ 0.6 cm2/m2 ) . 5 . Subject symptomatic aortic stenosis demonstrate NYHA Functional Classification Class II , great symptom aortic stenosis ( e.g . syncope ) . 6 . Subject deem high operable risk prefer TAVI delivery route alternate access ( subclavian/axillary direct aortic ) per medical opinion center 's heart team . High risk define STS mortality &gt; 8 % documented heart team agreement ≥ high risk SAVR due frailty comorbidities 1 . Subject unwilling unable comply studyrequired followup evaluation . 2 . Subject documented history cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within 6 month ( less equal 180 day ) prior index procedure . 3 . Subject carotid artery disease require intervention . 4 . Subject evidence acute STsegment elevation myocardial infarction ( MI ) within 30 day prior patient index procedure ( define : ST Segment Elevation evidence 12 Lead ECG ) . 5 . Subject native aortic valve congenitally unicuspid , bicuspid , quadricuspid noncalcified see echocardiography . 6 . Subject severe mitral valvular regurgitation . 7 . Subject severe mitral stenosis . 8 . Subject preexist prosthetic cardiac device , valve , prosthetic ring position . 9 . Subject refuse blood product transfusion . 10 . Subject resting leave ventricular ejection fraction ( LVEF ) less 20 % . 11 . Subject document , untreated symptomatic coronary artery disease ( CAD ) require revascularization . 12 . Subject percutaneous interventional invasive cardiovascular peripheral vascular procedure less equal 14 day prior index procedure . 13 . Subject severe basal septal hypertrophy would interfere transcatheter aortic valve placement . 14 . Subject history , currently diagnose , endocarditis . 15 . There image evidence intracardiac mass , thrombus , vegetation . 16 . Subject consider hemodynamically unstable ( require inotropic support mechanical heart assistance ) . 17 . Subject acute pulmonary edema require intravenous diuretic therapy stabilize heart failure . 18 . Subject severe pulmonary disease determine STS score . 19 . Subject chronic oral steroid therapy . 20 . Subject documented hypersensitivity contraindication anticoagulant antiplatelet medication . 21 . Subject renal insufficiency evidence serum creatinine great 3.0 mg/dL ( 265.5 µmol/L ) endstage renal disease require chronic dialysis . 22 . Subject morbid obesity define BMI great equal 40 . 23 . Subject ongoing infection sepsis . 24 . Subject uncontrolled blood dyscrasia define : leukopenia ( WBC &lt; 3000 mm3 ) , acute anemia ( Hb &lt; 9 mg/dL ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 , ) . 25 . Anatomy fall outside recommend value IFU , unless specifically approve Subject Selection Committee . 26 . Subject active peptic ulcer gastrointestinal ( GI ) bleed within 90 day prior index procedure . 27 . Subject currently participate another investigational drug device study , unless approve Sponsor . 28 . Subject has/had emergency surgery reason within 30 day index procedure . 29 . Subject life expectancy le 1 year . 30 . Subject medical , social psychological condition , opinion Principal Investigator Subject Selection Committee , preclude subject study participation . 31 . Subject diagnose state dementia would fundamentally complicate rehabilitation procedure compliance followup visit . 32 . Subject document allergy contrast medium adequately treat , nitinol alloy , porcine tissue , bovine tissue . Transaortic Subject Cohort Specific Exclusion Criteria 1 . Subject chest condition ( anatomical otherwise ) prevents TAo access . 2 . Subject preexist patent RIMA graft would preclude access . 3 . Subject porcelain aorta , define extensive circumferential calcification ascend aorta would complicate TAo access . Subclavian/Axillary Subject Cohort Specific Exclusion Criteria 1 . Subject 's access vessel ( subclavian/axillary ) diameter allow introduction 18/19 Fr delivery system . 2 . Subject 's subclavian/axillary artery severe calcification and/or tortuosity . 3 . Subject history LIMA/RIMA graft would preclude access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TAVI</keyword>
	<keyword>Valvular heart disease</keyword>
	<keyword>Transcatheter aortic valve implantation</keyword>
</DOC>